Prolight Diagnostics AB (NGM:PRLD) Additional Paid-In Capital: kr279.88 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:PRLD Prolight Diagnostics AB NGM:PRLD
30 GF Score
Price kr19.48
! 2 Warning Signs
View Full Analysis

What is Prolight Diagnostics AB Additional Paid-In Capital?

Prolight Diagnostics AB NGM:PRLD -6.35% 30 Additional Paid-In Capital is kr279.88 Mil as of Jun. 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.


Prolight Diagnostics AB's quarterly additional paid-in capital stayed the same from Dec. 2025 (kr279.88 Mil) to Mar. 2026 (kr279.88 Mil) and stayed the same from Mar. 2026 (kr279.88 Mil) to Jun. 2026 (kr279.88 Mil).

Prolight Diagnostics AB's annual additional paid-in capital increased from Dec. 2023 (kr237.23 Mil) to Dec. 2024 (kr237.87 Mil) and increased from Dec. 2024 (kr237.87 Mil) to Dec. 2025 (kr279.88 Mil).

Prolight Diagnostics AB Additional Paid-In Capital Related Terms

Prolight Diagnostics AB Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Prolight Diagnostics AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prolight Diagnostics AB Additional Paid-In Capital Chart

Prolight Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.48 195.60 237.23 237.87 279.88

Prolight Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.73 279.92 279.88 279.88 279.88
NGM:PRLD
30GF Score
Prolight Diagnostics AB NGM:PRLD
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prolight Diagnostics AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of kr279.88 Mil mean?
Prolight Diagnostics AB (NGM:PRLD) has a Additional Paid-In Capital of kr279.88 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Prolight Diagnostics AB and its competitors.
Is Prolight Diagnostics AB's Additional Paid-In Capital too high?
Prolight Diagnostics AB's current Additional Paid-In Capital is kr279.88 Mil. Overall, Prolight Diagnostics AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's Additional Paid-In Capital compare to ISRG and BDX?
Prolight Diagnostics AB's Additional Paid-In Capital of kr279.88 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Prolight Diagnostics AB and its competitors. Prolight Diagnostics AB's current Additional Paid-In Capital is kr279.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current Additional Paid-In Capital of kr279.88 Mil. The current Additional Paid-In Capital is kr279.88 Mil. Prolight Diagnostics AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current Additional Paid-In Capital is kr279.88 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prolight Diagnostics AB Business Description

Address Gasverksgatan 3A, Lund, SWE, 222 29
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
30GF Score

Get the complete analysis for NGM:PRLD

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.48
Price